Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

2.

MAGE: the spell is broken.

Rezvani K.

Clin Cancer Res. 2011 Nov 15;17(22):6955-7. doi: 10.1158/1078-0432.CCR-11-2302. Epub 2011 Nov 8.

3.

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.

Bao L, Dunham K, Lucas K.

Cancer Immunol Immunother. 2011 Sep;60(9):1299-307. doi: 10.1007/s00262-011-1037-z. Epub 2011 May 28.

PMID:
21626030
4.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.

Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM.

Blood. 1998 Apr 15;91(8):2925-34.

5.

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/╬│cnull mice.

Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, Ikeda H, Shiku H.

Cancer Sci. 2012 Jan;103(1):17-25. doi: 10.1111/j.1349-7006.2011.02111.x. Epub 2011 Nov 8.

6.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE.

J Exp Med. 2004 Dec 20;200(12):1623-33.

7.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM.

Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.

8.

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C.

Blood. 2010 Sep 16;116(11):1908-18. doi: 10.1182/blood-2009-11-249474. Epub 2010 Jun 8.

9.

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.

Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM.

Cancer Gene Ther. 2004 Feb;11(2):81-91.

PMID:
14685154
10.

A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.

Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P.

Eur J Immunol. 1999 Oct;29(10):3329-37.

11.

Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.

Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.

Eur J Immunol. 2006 Mar;36(3):593-602.

12.

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.

Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE.

Leuk Lymphoma. 2006 May;47(5):837-42.

PMID:
16753867
13.

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K.

Tumour Biol. 2014 Jun;35(6):5753-62. doi: 10.1007/s13277-014-1764-9. Epub 2014 Mar 2.

PMID:
24584817
14.

MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.

Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P.

Cancer Immunol Immunother. 2011 Jan;60(1):23-35. doi: 10.1007/s00262-010-0916-z. Epub 2010 Sep 21.

PMID:
20857101
15.

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.

Blood. 2003 Mar 1;101(5):1905-12. Epub 2002 Oct 31.

16.

Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S.

Surgery. 2013 Dec;154(6):1456-62; discussion 1462. doi: 10.1016/j.surg.2013.07.009.

17.

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.

Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG.

Cancer Immunol Immunother. 2015 Oct;64(10):1251-60. doi: 10.1007/s00262-015-1731-3. Epub 2015 Jun 24.

PMID:
26105625
18.

Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, Shaughnessy J Jr, Barlogie B, Prentice HG, van Rhee F.

Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20.

19.

Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.

Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E, Tellam J, Marlton P, Seymour JF, Gandhi M, Khanna R.

J Immunol. 2006 Oct 1;177(7):4897-906.

20.
Items per page

Supplemental Content

Write to the Help Desk